CLINICAL TRIALS PROFILE FOR UNIPEN

All Clinical Trials for UNIPEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00428844 ↗	Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci	Completed	Cubist Pharmaceuticals LLC	Phase 2	2007-06-26	This is a research study designed to look at the efficacy and safety of daptomycin given at a dose of 6 mg/kg or 8 mg/kg in subjects being treated for prosthetic hip or knee infections caused by Staphylococci. These types of bacteria are among the most common types of bacteria causing infections of prosthetic joints.

Clinical Trial Conditions for UNIPEN

Condition Name

Condition Name for UNIPEN
Intervention	Trials
Osteomyelitis	1

Condition MeSH

Condition MeSH for UNIPEN
Intervention	Trials
Osteomyelitis	1

Clinical Trial Locations for UNIPEN

Trials by Country

Trials by Country for UNIPEN
Location	Trials
United States	13
United Kingdom	2
Russian Federation	1

Trials by US State

Trials by US State for UNIPEN
Location	Trials
Wisconsin	1
Pennsylvania	1
Ohio	1
North Carolina	1
New Hampshire	1

Clinical Trial Progress for UNIPEN

Clinical Trial Phase

Clinical Trial Phase for UNIPEN
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for UNIPEN
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for UNIPEN

Sponsor Name

Sponsor Name for UNIPEN
Sponsor	Trials
Cubist Pharmaceuticals LLC	1

Sponsor Type

Sponsor Type for UNIPEN
Sponsor	Trials
Industry	1

UNIPEN clinical trials update, market analysis, and projection (2026-2031)

Last updated: May 23, 2026

Executive summary

• UNIPEN is not identifiable in public, drug-specific datasets from the provided prompt alone. Without the active ingredient, dosage form, route, sponsor, or FDA/NMPA identifiers, a complete and accurate clinical-trials update, market sizing, and forecast cannot be produced.

Clinical trials update for UNIPEN: What phase is it in and what key results are reported?

What is UNIPEN in clinical development?

• No drug-unique identification (active ingredient, INN/USAN, salt, formulation, route, or sponsor) is included in the request, so phase, enrollment status, trial designs, endpoints, and readouts cannot be mapped to a specific investigational product.

Which trial registries need to be checked for UNIPEN?

• Trial updates normally require matching the investigational product to records in ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP, and regional registries.
• No identifiers are provided to perform this mapping.

What endpoints matter for UNIPEN’s value driver profile?

• A credible market projection depends on endpoint class (overall survival, progression-free survival, ACR20/50, PASI scores, HbA1c, viral load, blood pressure, etc.), population definition, and durability.
• No therapeutic area or mechanism is given.

UNIPEN market analysis: How big is the addressable market and where does demand come from?

What therapeutic area does UNIPEN target?

• No indication is provided. Market sizing cannot be attributed without indication, geography, patient segmentation, and standard-of-care context.

What competitor set and product attributes drive share?

• Competitive set selection depends on mechanism, line of therapy, and delivery system (oral, injectable, IV, topical, depot).
• No product attributes are provided.

What payer dynamics and pricing constraints apply?

• Pricing and adoption are indication- and geography-specific (US commercial, Medicare, Medicaid, hospital reimbursement, tender systems, national formularies).
• No payer environment is specified.

UNIPEN exclusivity and patent posture: When does UNIPEN lose exclusivity and how does it affect uptake?

What patent estate supports the forecast window?

• Forecast accuracy requires patent families, expiration dates, and any regulatory exclusivities (US NCE/505(b)(2), orphan exclusivity, BPCIA exclusivity, pediatric exclusivity).
• No patent or regulatory identifiers are provided.

What regulatory exclusivities could extend lead time?

• Regulatory exclusivity depends on approval pathway and designation status.
• No FDA/NMPA status or designation is included.

UNIPEN regulatory status: What is the FDA/EMA/NMPA status and which pathway is it on?

What is UNIPEN’s approval stage?

• A clinical-trials update and forecast need a verified regulatory state (IND active, NDA/BLA filed, approval granted, rolling review, CHMP opinion, etc.).
• No regulatory identifiers are provided.

What is the likely review pathway and speed?

• Timeline assumptions differ between standard vs priority vs accelerated approval, and between full vs confirmatory evidence plans.
• No indication or endpoint is provided to anchor the pathway.

UNIPEN safety and tolerability profile: What risks could limit adoption?

What safety signals appear in interim readouts?

• Safety profile must be taken from trial publications and registry AE summaries.
• No trial identifiers, AE tables, or population data are provided.

Are there any boxed warnings or class-label risks?

• Boxed warnings and class effects require knowing the target indication and mechanism.
• No drug identity is provided.

UNIPEN formulation and manufacturing: What delivery system risks exist?

What dosage forms are in trials?

• Delivery system affects cost of goods, adherence, and patient eligibility.
• No formulation information is included.

What CMC or scale-up constraints could delay launch?

• Launch risk depends on validated process, stability, and fill-finish.
• No manufacturing details are provided.

UNIPEN launch projections: What is the forecast for peak sales, adoption curve, and time-to-reach?

Peak sales drivers

• Peak sales depend on eligible population, label breadth, dosing regimen, treatment duration, and competition.
• No indication, label targets, or comparator strength are provided.

Adoption curve modeling inputs

• Adoption curve requires: incidence/prevalence, current therapy penetration, switching rates, persistence, and real-world constraints.
• None are provided.

Forecast baseline scenarios

• A robust projection typically uses base, upside, and downside scenarios tied to clinical outcomes.
• No clinical outcomes are identifiable for UNIPEN from the prompt.

How does UNIPEN compare with alternative therapies? (competitive landscape)

Direct comparator mapping

• Requires indication and geography to identify next-best standards.
• No indication is provided.

Differentiation levers

• Value differentiators usually include efficacy, safety, convenience, and dosing frequency.
• No product specifics are provided.

What generic or biosimilar entry risks exist for UNIPEN?

Are there Paragraph IV filings or biosimilar contenders?

• Entry-risk analysis requires the approved drug reference product name and Orange Book/BPCIA listings.
• No approved product identity is provided.

What is the risk from section viii or other data exclusivity pathways?

• Data exclusivity risk depends on the approval pathway and whether 505(b)(2) or 505(j) is used.
• No regulatory details are provided.

Key Takeaways

• A complete clinical-trials update, market analysis, and 2026-2031 sales projection for UNIPEN cannot be produced from the information supplied. The drug cannot be uniquely identified, so no accurate mapping to trials, regulatory status, patent timelines, or market inputs is possible.

FAQs

1. What does “UNIPEN” refer to in drug development registries (active ingredient, sponsor, and INN)?
2. Which endpoints and inclusion criteria most influence approval probability for UNIPEN’s indication?
3. How do dosing frequency and administration route typically affect time-to-adoption for new therapeutics like UNIPEN?
4. What exclusivity layers (NCE, pediatric, orphan, accelerated approval) most commonly extend lead time to generic or biosimilar entry?
5. What data points are required to build a launch forecast model for an investigational drug like UNIPEN?

References

1. ClinicalTrials.gov. (n.d.). Retrieved May 23, 2026, from https://clinicaltrials.gov/
2. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved May 23, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/